Psychedelics can be produced in yeast

Psilocybin mushrooms have been found to have minimal harmful effects and could potentially benefit those with depression. But they remain illegal even though they offer a groundbreaking alternative to several under-treated psychological conditions.

Nevertheless, psychedelics are currently riding a wave of positive momentum brought on by cannabis, and if psilocybin gets approved as a pharmaceutical drug, production in yeast appears to be the most commercially viable option.

It's infeasible and way too expensive to extract psilocybin from magic mushrooms and the best chemical synthesis methods require expensive and difficult to source starting substrates. Thus, there is a need to bring down the cost of production and to provide a more consistent supply chain."

Nick Milne, former Postdoc at DTU Biosustain and CSO and Co-founder of Octarine Bio

Bio-based production of psilocybin has gained big interest and researchers have already proved small-scale production in E. coli. However, production in bacteria comes with a wide range of concerns which can be addressed by using yeast instead.

In yeast, the scientists prove that psilocybin can be produced de novo, which means that you can produce the molecule by simply growing the yeast with sugar and other nutrients, without the need to add any other starting substrates.

Producing psilocybin de novo in E. coli is difficult since a key enzyme in the biosynthetic pathway doesn't work in bacteria, and so to get around this problem you need to add an expensive starting substrate, making the whole production process too costly.

"Since yeast and Psilocybe mushrooms are quite closely related species, this enzyme works very well in yeast, providing a much more cost-efficient alternative," says group leader at DTU Biosustain Irina Borodina.

Additionally, yeast also performs better in large-scale fermentation due to its long history in the beer brewing process, and also in the purification process since E. coli produces additional potentially harmful compounds that you would not like to have in your final product.

Source:
Journal reference:

Milne, N., et al. (2020) Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives. Metabolic Engineering. doi.org/10.1016/j.ymben.2019.12.007.

Comments

  1. Fred Hosea Fred Hosea Ecuador says:

    This grows naturally already as a mushroom.  People can grow their own, or buy mushrooms through local farmer markets.  What is the need to turn this into a complicated biochemistry and commercialization affair that will be regulated, require prescriptions, and then force users to pay higher prices and enrich the big pharma industry?   The question is rhetorical.  Humans have used these mushrooms for millennia without the need for medicalization and commercialization.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New breakthrough may help cure prion disease